Panion prepares for USA

Panion Animal Health AB develops a novel treatment for epilepsy in dogs and targets the American market first. In week 43, 2018, Panion is invited to a meeting with the USFDA in Washington DC where the development product will be presented for authority reviewers from both FDA and USDA. From Panion, three persons will participate in person; regulatory FDA-expert Dave Petrick, Director of Business development Carlos N. Velez, and CEO, DVM Anja Holm. In addition, the FDA project manager has accepted to establish a telephone connection to two of Panion's scientific experts, so they can listen in and answer specific questions.

"We are really excited that this important meeting is taking place now. A presubmission meeting with the authorities, who will evaluate the application in the end, is of utmost importance. We have prepared and submitted a long document to the FDA including a list of questions that we expect to get the reviewers feed-back on. This will help us make the development plan as concrete as possible, including getting a firm estimate of the development costs and timelines." says Anja Holm.

Panion is also progressing the next step in the development plan after the recently finalized safety study in dogs; a pilot study in family dogs with true drug-refractory epilepsy. In the same week, meetings will be held at the investigator clinic, which is an optimal choice of clinic because of its large size, full equipment, and the highly skilled staff, including veterinary neurosurgeons and neurologists. The meetings will concern details of the study plan, roles, responsibilities and timelines.

"The expert neurologists at the clinic are very interested in our innovative treatment for this group of dogs that are currently lacking good treatment options, and they seem optimistic with regards to the speed of enrollment in the study, which is very encouraging for us. We aim at good progress in the pilot-study and expect to send out further details when we are back from the tour" says Anja Holm.

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com 

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer


Panion starts clinical study in dogs

Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC ("LIVS") in New York, USA. It is a pilot study to evaluate the efficacy of the treatment in patient dogs with idiopathic epilepsy. It is the first time that the gene therapy treatment is made available for client-owned family dogs.


Invitation to investor meeting in Stockholm, Friday 14th of December 2018, 12-13

Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 - 13.


Final dog study results


Memorandum publicerat

Investeringsmemorandum - Styrelsen för Panion Animal Health AB (publ) publicerar inbjudan att teckna aktier i Bolaget.

Teckningsperiod: 7 december 2018 - 21 december 2018

Teckningskurs: 1 SEK per aktie.



Panion Animal Health AB genomför företrädesemission om cirka 7,7 MSEK

Panion meddelar idag att styrelsen i Panion Animal Health AB ("Panion" eller "Bolaget") den 28 november 2018, med stöd av bemyndigande lämnat vid årsstämman den 29 maj 2018, beslutat att genomföra en nyemission av 7 687 374 aktier med företrädesrätt för befintliga aktieägare. Teckningskursen i nyemissionen är 1 krona vilket vid full teckning kommer att tillföra bolaget cirka 7,7 Mkr före emissionskostnader om cirka 0,2 Mkr.


Article in Animal Pharm nov 23

Panion targets gene therapy pilot study in North America


2018 Q3 report, Period July-September for Panion Animal Health AB

Period July-September

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -536 (-923).
  • Earnings per share: SEK -0,03 (-0,25).
  • Liquidity at the end of the period: kSEK 1 987 (1 166).

Period January-September

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -2 532 (-3 501).
  • Earnings per share: SEK -0,03 (-0,25).
  • Liquidity at the end of the period: kSEK 1 987 (1 166).


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: